An Early Prospective Study of the Traq™ Device for Characterization of Binocular Ocular Function in Normal Subjects and Subjects With Recent Traumatic Brain Injury
Rebiscan, Inc. · NCT07742878
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 12+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 10
- US sites recruiting
- 1
- Study start
- July 14, 2026
- Record last updated
- August 3, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The early prospective study of Traq™ (an investigational binocular ophthalmic neurodiagnostic device) will measure binocular ocular functions (bilateral foveal fixation, foveal binocularity, and fovea-tracked saccadic latency) in normal subjects and those with history of mild-to moderate traumatic brain injury (mTBI).
Being studied: Binocular ophthalmic neurodiagnostic device
Conditions: Mild Traumatic Brain Injury, Concussion; Binocular Visual Function; Neuro-Ophthalmology; Saccadic Eye Movements
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 12 years or older at the time of enrollment.
- Able to understand and sign an informed consent form (or with parent/guardian for subjects less than 18 years of age).
- Willing and able to complete all required study visits and test assessments.
- Subjects with no history of traumatic brain injury (normal arm).
- Subjects with a history of mild to moderate traumatic brain injury (mTBI) within the last six months, (post-TBI arm).
Exclusion Criteria
- Concurrent participation in another drug or device clinical investigation.
- Subject with a history of eye disease which could reduce, or limit reflected polarized light from the retina, such as corneal scarring, cataract, glaucoma, degenerative retinal conditions (e.g., age-related macular degeneration, diabetic retinopathy), or other conditions which may decrease device signal reflectance.
- Subjects who are pregnant, planning to become pregnant, or are breastfeeding.
Recruiting US locations
Elite Eye Care/Elite Vision Therapy
Waukee, IA 50263
Site contact: Heidi Bell, OD · 515-987-3937 · heidibellod@gmail.com
Study contacts (from the official record)
- Justin Shaka · 857-600-0982 · jgshaka@rebiscan.com
Similar studies in Iowa
All neurology studies in Iowa →- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Iowa City, IA + 35 other US sites
- Eligibility basics
- Ages 18–65
- Recruiting
Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
RapidPulse, Inc
- Location
- Iowa City, IA + 12 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- West Des Moines, IA + 111 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Ames, IA + 35 other US sites
- Eligibility basics
- Ages 18–75